MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
1.430
+0.080
+5.93%
After Hours: 1.550 +0.12 +8.39% 18:20 04/17 EDT
OPEN
1.340
PREV CLOSE
1.350
HIGH
1.485
LOW
1.330
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
5.25
52 WEEK LOW
1.105
MARKET CAP
380.56M
P/E (TTM)
-1.6536
1D
5D
1M
3M
1Y
5Y
1D
Catalyst Watch: Spotlight on Tesla, Alphabet earnings, AACR drug data, and global PMI reports
Seeking Alpha · 11h ago
Weekly Report: what happened at AUTL last week (0407-0411)?
Weekly Report · 4d ago
Promising Outlook for Autolus Therapeutics: Operational Efficiency and Strategic Positioning Drive Buy Rating
TipRanks · 04/10 10:40
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 04/09 21:05
Weekly Report: what happened at AUTL last week (0331-0404)?
Weekly Report · 04/07 09:11
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By 12%
Simply Wall St · 04/04 12:19
Autolus Therapeutics Announces Leadership Transition in Finance
TipRanks · 04/03 20:33
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Barchart · 04/02 06:00
More
About AUTL
More
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Recently
Symbol
Price
%Change

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.